Browsing Tag
pediatric endocrinology
2 posts
Can Ascendis Pharma’s TransCon CNP still win FDA approval after the review extension?
FDA delays decision on Ascendis Pharma’s dwarfism drug TransCon CNP to February 2026 due to protocol revisions. See how this affects approval odds and launch.
Eton Pharmaceuticals shocks investors with major acquisition: Shares explode to 52-week high
Eton Pharmaceuticals has sent shockwaves through the pharmaceutical industry after its shares soared to a 52-week high, fueled…